Mark Cuban Foundation and CSL Bring AI Bootcamp to Philadelphia Teens
ARS Pharmaceuticals Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement With CSL Seqirus for Commercialization of Neffy in Australia and New Zealand
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
Friday, the FDA approved Pfizer Inc's (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or h
Travere, CSL Win Conditional Nod for Kidney Disease Therapy in EU
CureVac Posts Early Efficacy Results for GSK-partnered Flu Shot
Akebia Stock Jumps as FDA Clears Renal Anemia Therapy
Kyowa Kirin's Rare Disease Therapy Becomes World's Most Expensive Drug
Ferinject Approved by Health Canada for the Treatment of Iron Deficiency Anemia in Adult...
CSL Ltd's Dividend Analysis
CSL Goes Ex Dividend Tomorrow
'Tripledemic' Burden Lower This Winter Despite COVID Impact: Airfinity
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe Positive CHMP opinion is
Travere Therapeutics Gains as EU Backs Kidney Disease Therapy
CSL LTD SPON ADR EACH REPR 0.5 ORD To Go Ex-Dividend On March 11th, 2024 With 0.595 USD Dividend Per Share
February 15th - $CSL LTD SPON ADR EACH REPR 0.5 ORD(CSLLY.US)$ is trading ex-dividend on March 11th, 2024. Shareholders of record on March 12th, 2024 will receive 0.595 USD dividend per share. The
Earnings Call Summary | CSL LTD SPON ADR EACH REPR 0.5 ORD(CSLLY.US) Q2 2024 Earnings Conference
The following is a summary of the CSL Ltd (CSLLY) Q2 2024 Earnings Call Transcript:Financial Performance:CSL reported revenue of $8.1 billion, an increase of 11% at constant currency.CSL's NPATA was $
CSL Limited Falls After Phase 3 Setback for Key Trial
CSL Announces Top-line Results From the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety...
Masking Returns to Some U.S. Hospitals Amid Rising COVID, Flu Cases
Pfizer Wins Canada Approval for Hemophilia B Gene Therapy
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation MRNA Vaccine Booster
Data follow approval of the world's first Self-Amplifying messenger RNA (sa-mRNA) COVID-19 Vaccine for Adults by Japan Ministry of Health, Labor and Welfare.
No Data